Skip NavigationSkip to Content

Perplexing paradoxical reactions: navigating the complexity of protracted tuberculosis meningitis-a case report

  1. Author:
    Gooding,Megan
    Hammoud, Dima A
    Epling, Brian
    Rocco, Joseph
    Laidlaw, Elizabeth
    Kuriakose,Safia
    Chaturvedi, Mansi
    Galindo, Frances
    Ma, Stella V
    Mystakelis, Harry
    Poole, April
    Russo, Kelly
    Shah, Maunank
    Malone, Joseph L
    Rupert,Adam
    Sereti, Irini
    Manion, Maura
  2. Author Address

    Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, United States., Center for Infectious Disease Imaging, NIH Clinical Center, NIH, Bethesda, MD, United States., National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States., Division of Pulmonary and Critical Care Medicine, University of Maryland, Baltimore, Baltimore, MD, United States., Division of Pulmonary Medicine, National Heart, Lung, and Blood Institutes, National Institutes of Health, Bethesda, MD, United States., Howard County Department of Health, Columbia, MD, United States., Department of Health, Baltimore City TB Program, Baltimore, MD, United States., Montgomery County Department of Health, Silver Spring, MD, United States., AIDS Monitoring Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.,
    1. Year: 2024
    2. Date: Oct 31
    3. Epub Date: 2024 10 31
  1. Journal: Frontiers in Immunology
    1. 15
    2. Pages: 1441945
  2. Type of Article: Article
  3. Article Number: 1441945
  1. Abstract:

    Tuberculous meningitis (TBM) has considerable mortality and morbidity, and it often presents therapeutic challenges when complicated by paradoxical reactions (PRs). Here, the clinical course of four cases of TBM patients complicated by PRs in a longitudinal TB cohort is described while also providing insights from the larger clinical cohort. Research flow cytometry, biomarker analysis, and drug concentrations were performed on available samples. All participants were initiated on standard antituberculosis therapy (ATT) and enrolled at the onset of PRs (PR group) or 2-4 months after the start of ATT (controls). The four TBM participants highlighted here presented with fevers, headaches, neurological deficits, and fatigue at the initial presentation. Upon diagnosis, all were initiated on rifampin, isoniazid, pyrazinamide, and ethambutol (RHZE) at standard doses and on corticosteroids. The median time to first PR was 37 days with recrudescence of initial TBM signs and symptoms at the time of PR. At the time of referral, all participants had low drug concentrations requiring dose optimization and regimen intensification as well as recrudescent flares upon corticosteroid taper, with one individual developing enlargement of tuberculoma 1 year following completion of ATT. Based on biomarkers and flow cytometry, PRs are characterized by elevated interferon-gamma and ferritin levels in the plasma compared to controls. In the TBM participants, T-cell activation with elevated levels of inflammatory biomarkers in the cerebrospinal fluid (CSF) was seen at the time of PR. These unique and highly detailed TBM cases provide insights into the pathogenesis of PRs, which may assist with future diagnostics and treatment. Copyright © 2024 Gooding, Hammoud, Epling, Rocco, Laidlaw, Kuriakose, Chaturvedi, Galindo, Ma, Mystakelis, Poole, Russo, Shah, Malone, Rupert, Sereti and Manion.

    See More

External Sources

  1. DOI: 10.3389/fimmu.2024.1441945
  2. PMID: 39559357
  3. PMCID: PMC11570994

Library Notes

  1. Fiscal Year: FY2024-2025
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel